Asunto(s)
Leucemia Mieloide Aguda/diagnóstico , Leucemia Prolinfocítica/diagnóstico , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Humanos , Leucemia Mieloide Aguda/sangre , Leucemia Mieloide Aguda/tratamiento farmacológico , Leucemia Prolinfocítica/sangre , Leucemia Prolinfocítica/tratamiento farmacológico , Linfocitos/efectos de los fármacos , Linfocitos/patología , Masculino , Persona de Mediana EdadRESUMEN
T-prolymphocytic leukemia (T-PLL) is a rare malignancy of mature T-cells with distinct clinical, cytomorphological, and molecular genetic features. The disease typically presents at an advanced stage, with marked leukocytosis, B symptoms, hepatosplenomegaly, and bone marrow failure. It usually follows an aggressive course from presentation, and the prognosis is often considered dismal; the median overall survival is less than one year with conventional chemotherapy. This case report describes a patient with T-PLL who, after an unusually protracted inactive phase, ultimately progressed to a highly invasive, organ-involving disease. After initial treatments failed, a novel treatment approach resulted in a significant response.
Asunto(s)
Leucemia Prolinfocítica de Células T , Leucemia Prolinfocítica , Humanos , Alemtuzumab/uso terapéutico , Leucemia Prolinfocítica/diagnóstico , Leucemia Prolinfocítica/genética , Leucemia Prolinfocítica/terapia , Leucemia Prolinfocítica de Células T/diagnóstico , Leucemia Prolinfocítica de Células T/genética , Leucemia Prolinfocítica de Células T/terapiaRESUMEN
Translocations involving MYC are rare in chronic lymphocytic leukemia (CLL), and up to now, their prognostic significance remains unclear. We report the characteristics of 21 patients with CLL and nine patients with prolymphocytic leukemia (PLL), diagnosed in multiple centers (n = 13), which showed an MYC translocation demonstrated by fluorescence in situ hybridization. The prevalence was estimated to be <1%. Advanced age and male predominance were observed. Morphological analysis frequently revealed the presence of prolymphocytes. A typical "CLL-immunophenotype" was found in four of nine cases with PLL. Moreover, CD5 and CD23 were frequently expressed in PLL. The latter findings are atypical for PLL and may suggest transformation or progression of an underlying CLL. MYC translocations were frequently observed with concomitant adverse cytogenetic markers, such as del(11q) (n = 8/30) and/or del(17p)/monosomy 17 (n = 7/30). In addition, the presence of unbalanced translocations (n = 24 in 13/30 cases) and complex karyotype (n = 16/30) were frequent in cases with MYC translocations. Altogether, del(17p)/monosomy 17, del(11q), and/or complex karyotype were observed in 22 of 30 patients. Survival outcome was poor: the median time to treatment was only 5 months, and overall survival (OS) from clinical diagnosis and from genetic detection was 71 and 19 months, respectively. In conclusion, CLL/PLL with MYC translocations is a rare entity, which seems to be associated with adverse prognostic features and unfavorable outcome.
Asunto(s)
Cromosomas Humanos Par 8 , Genes myc/genética , Leucemia Linfocítica Crónica de Células B/genética , Leucemia Prolinfocítica/genética , Translocación Genética , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Cromosomas Humanos Par 14/genética , Cromosomas Humanos Par 2/genética , Cromosomas Humanos Par 22/genética , Cromosomas Humanos Par 8/genética , Estudios de Cohortes , Progresión de la Enfermedad , Femenino , Humanos , Leucemia Linfocítica Crónica de Células B/clasificación , Leucemia Linfocítica Crónica de Células B/diagnóstico , Leucemia Linfocítica Crónica de Células B/patología , Leucemia Prolinfocítica/clasificación , Leucemia Prolinfocítica/diagnóstico , Leucemia Prolinfocítica/patología , Masculino , Persona de Mediana Edad , Invasividad Neoplásica , Estudios RetrospectivosRESUMEN
B-cell chronic lymphocytic leukaemia and the similar diseases are seen predominantly in patients above the age 50 years, i.e. at the age when the patients also have other co-morbidities. The knowledge of these diseases on molecular level has improved significantly over the last decade. Molecular and biological prognostic factors are available in routine everyday practice. Assessment of these factors enables prediction of prognosis and, in some cases, also the response to therapy. The aim of the present review is to provide the medical community with the main information on this disease as patients with B-cell chronic lymphocytic leukaemia and similar disease states are of older age and very often suffer from a range of co-morbidities. Consequently, care for these patients involves physicians from various specialities. The aim of the following text is to present a clear overview of the basic information about this group of diseases that might be useful to all physicians who provide care to patients with B-cell chronic lymphocytic leukaemia and similar conditions. Since monoclonal immunoglobulin is sometimes identified in patients with these diseases, it is important to consider these conditions in the differential diagnosis of the states with the presence of monoclonal immunoglobulin.
Asunto(s)
Leucemia Linfocítica Crónica de Células B/diagnóstico , Diagnóstico Diferencial , Humanos , Leucemia de Células Pilosas/diagnóstico , Leucemia Prolinfocítica/diagnóstico , Mieloma Múltiple/diagnóstico , Paraproteinemias/diagnósticoRESUMEN
INTRODUCTION: Post-transplant lymphoproliferative disorder is a serious disorder which occurs post hematopoietic stem cell transplant or solid organ transplantation. T-prolymphocytic leukemia is a T cell type monomorphic post-transplant lymphoproliferative disorder which accounts for only 2% of all mature lymphocytic leukemias in adults over the age of 30. CASE PRESENTATION: A 59-year-old man of Chinese ethnicity presented to our hematology unit with headache, lethargy, and exertional dyspnea for the past 1 month. He underwent an uneventful cadaveric renal transplant 20 years ago for chronic glomerulonephritis-induced end-stage renal disease. He had been on long-term immunosuppressants since then consisting of orally administered prednisolone 10 mg daily and orally administered cyclosporine A 50 mg twice daily. On examination, he was pale with a palpable liver and spleen. He had a functioning renal graft. Marrow flow cytometry confirmed T-prolymphocytic leukemia with lymphocytes expressing CD2, CD3, CD7, CD52, and TCL-1. His human T-cell lymphotropic virus and Epstein-Barr virus serology and deoxyribonucleic acid (DNA) were negative. He was treated with one cycle of cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy to which he failed to respond. In view of his renal allograft, he was not suitable for alemtuzumab due to the risk of nephrotoxicity. He was given orally administered venetoclax but he died on day 17 due to severe auto tumor lysis syndrome. CONCLUSION: The place of immunophenotyping in the diagnosis and treatment of this disorder is of significant importance. More research needs to be carried out to further comprehend the pathophysiology and treatment modalities for this disorder.
Asunto(s)
Trasplante de Riñón/efectos adversos , Trastornos Linfoproliferativos/diagnóstico , Errores Diagnósticos , Resultado Fatal , Humanos , Inmunofenotipificación/métodos , Leucemia Prolinfocítica/diagnóstico , Trastornos Linfoproliferativos/inmunología , Masculino , Persona de Mediana EdadRESUMEN
The diagnosis of chronic lymphocytic leukaemia (CLL) is based on clinical and laboratory features. Morphology and immunophenotype are the key initial diagnostic tests. In cases with atypical features, these investigations should be complemented with cytogenetics and/or histology to confirm the diagnosis and to exclude other B-cell disorders. Morphologically, CLL can be classified into typical and atypical forms. Cell-marker studies provide a robust foundation to establish the diagnosis as the lymphocytes have a distinct immunophenotypic signature. Although no single antigen is exclusively expressed in CLL cells, when several markers are compounded into a scoring system the results allow firming up of the diagnosis. Other immunological markers, such as CD38 or ZAP-70, have an important prognostic impact. Fluorescence in-situ hybridization (FISH) analysis also provides prognostic information, chiefly by detecting 17 (p53 locus) and 11q deletion, and may determine the type of therapy.
Asunto(s)
Leucemia Linfocítica Crónica de Células B/diagnóstico , Médula Ósea/patología , Diagnóstico Diferencial , Citometría de Flujo , Humanos , Inmunofenotipificación , Hibridación Fluorescente in Situ , Leucemia de Células Pilosas/diagnóstico , Leucemia Linfocítica Crónica de Células B/patología , Leucemia Prolinfocítica/diagnóstico , Linfocitos/patología , Pronóstico , Bazo/patologíaRESUMEN
We describe a 79-year-old man who had massive pleural effusion and a proliferation of prolymphocytic leukemia cells in the peripheral blood, bone marrow, and pleural effusion fluid. Immunophenotyping of leukemia cells revealed either CD3+CD4+CD8-CD25+ or CD3+CD4+CD8+CD25+. The antibody against human T-cell lymphotropic virus type I was negative. A diagnosis of T-PLL was made. The level of VEGF in the plasma or pleural effusion fluid was very high. Moreover, polymerase chain reaction analysis demonstrated an expression of VEGF mRNA in the leukemia cells, indicating a production of VEGF from leukemia cells and its involvement in the pathogenesis of T-PLL.
Asunto(s)
Leucemia Prolinfocítica/inmunología , Leucemia de Células T/inmunología , Factor A de Crecimiento Endotelial Vascular/biosíntesis , Anciano , Resultado Fatal , Perfilación de la Expresión Génica , Humanos , Leucemia Prolinfocítica/diagnóstico , Leucemia de Células T/diagnóstico , Masculino , Derrame Pleural Maligno/etiología , ARN Mensajero/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Factor A de Crecimiento Endotelial Vascular/genéticaRESUMEN
We report a case of a 64-year-old white female patient, who presented with symptomatic anemia (Hgb: 6.8g/dl), thrombocytopenia (platelets: 94,000/mcl) and leukocytosis (WBC: 156,000/mcl). Peripheral blood smear revealed markedly increased white blood cell count with predominance of atypical lymphoid cells of intermediate size, moderately dense chromatin, and prominent large single nucleoli. Bone marrow aspirate smear showed predominance (78%) of atypical lymphoid cells morphologically identical to those seen in the peripheral blood. The bone marrow core biopsy was hypercellular and packed with prominent infiltrate of prolymphocytes. Immunophenotypic analysis revealed a population of monoclonal cells (75% of all -erythroid cells) characterized by CD45+, CD19+, CD20+, CD5+, HLA-DR+, CD10-, CD23+/-, CD38+ and FMC7-. The abnormal cells were restricted to kappa light chain immunoglobulin with low intensity. Cytogenetic study showed an abnormal clone of eight cells with the following karyotype: 45,X,-X,add(8)(p11.2),t(8;14)(q24;q32),add(20)ql3[8]/46,XX[12]. The relative rarity of B-PLL and the heterogeneity of clinical and laboratory parameters make it difficult to define the natural history and prognosis in all cases. The optimal treatment for B-PLL is still unknown and to date there are no reports of chromosomal abnormalities as a prognostic factor. The patient was treated with six cycles of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Complete remission was achieved according to the criteria defined by National Cancer Institute Working Group for CLL.
Asunto(s)
Cromosomas Humanos Par 14 , Cromosomas Humanos Par 8 , Leucemia de Células B/genética , Leucemia Prolinfocítica/genética , Translocación Genética , Protocolos de Quimioterapia Combinada Antineoplásica , Aberraciones Cromosómicas , Ciclofosfamida , Doxorrubicina , Femenino , Humanos , Cariotipificación , Leucemia de Células B/diagnóstico , Leucemia de Células B/terapia , Leucemia Prolinfocítica/diagnóstico , Leucemia Prolinfocítica/terapia , Persona de Mediana Edad , Prednisona , VincristinaRESUMEN
The 2005 Society for Hematopathology/European Association for Haematopathology Workshop Session 1 was devoted to case presentations with discussions of 3 types of mature T-cell leukemias--T-cell prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sézary syndrome. These 3 disorders are clonal proliferations of postthymic alphabeta T cells that are often characterized by systemic manifestations and a leukemic blood picture. The application of clinical, morphologic, immunophenotypic, and genetic studies to the assessment and characterization of these 3 disorders is presented, along with specific diagnostic recommendations and differential diagnostic considerations.
Asunto(s)
Leucemia Prolinfocítica/diagnóstico , Leucemia de Células T/diagnóstico , Síndrome de Sézary/diagnóstico , Neoplasias Cutáneas/diagnóstico , Antígenos CD/metabolismo , Aberraciones Cromosómicas , Diagnóstico Diferencial , Humanos , Inmunofenotipificación , Leucemia Prolinfocítica/genética , Leucemia de Células T/genética , Síndrome de Sézary/genética , Neoplasias Cutáneas/genéticaRESUMEN
We report the clinical, ultrastructural, immunophenotypic and virological features of nine cases of a rare type of mature T cell disorder formerly designated Sezary cell leukaemia. All patients presented with lymphocytosis ranging from 12.7 to 133 x 10(9)/l, bone marrow infiltration, splenomegaly and lymphadenopathy. Skin involvement was absent at presentation but developed as a terminal event in two patients, one of whom showed a pattern of dermal infiltration different from that characteristic of Sezary syndrome. Cells from eight cases bore a mature T cell phenotype and electronmicroscopy revealed lymphocytes with cerebriform nuclei resembling Sezary cells. All cases except one were HTLV-I negative. Patients were treated with various chemotherapy regimens but with poor outcome, the median survival being 13 months. Laboratory and clinical data suggest great similarity between Sezary cell leukaemia and T prolymphocytic leukaemia (T-PLL), namely coexpression of CD4 and CD8 (3/9 cases), identical chromosomal abnormalities in the three cases studied (isochromosome 8q plus inversion 14 or t(X;14)(q28;q11)) and a remarkable sensitivity to CAMPATH-1H (complete remission of 21 months' duration in one patient), suggesting that this entity could be considered a variant form of T-PLL. The alternative diagnosis of adult T cell leukaemia/lymphoma could not be excluded in one patient in whom positive HTLV-I serology was documented.
Asunto(s)
Leucemia Prolinfocítica/diagnóstico , Leucemia de Células T/diagnóstico , Síndrome de Sézary/diagnóstico , Adulto , Anciano , Diagnóstico Diferencial , Femenino , Humanos , Leucemia Prolinfocítica/inmunología , Leucemia Prolinfocítica/patología , Leucemia de Células T/inmunología , Leucemia de Células T/patología , Masculino , Persona de Mediana Edad , Síndrome de Sézary/patologíaRESUMEN
We have investigated the role of immunophenotyping in distinguishing between leukemic B-cell lymphoproliferative disorders. Circulating cells from 666 cases were analyzed with a panel of markers by flow cytometry. The diseases included: chronic lymphocytic leukemia (CLL), 400; prolymphocytic leukemia, 22; hairy cell leukemia (HCL), 40; HCL variant, 15; splenic lymphoma with villous lymphocytes, 100; follicular lymphoma, 26; lymphoplasmacytic lymphoma, 25; mantle-cell lymphoma, 20; and large cell lymphoma, 18. On the basis of the most common marker profile in CLL, CD5+, CD23+, FMC7- and weak expression (+/-) of surface immunoglobulin (SmIg) and CD22, we devised a scoring system that gives for each of these five markers a value of 1 or 0 according to whether it is typical or atypical for CLL. Scores range from 5 (typical of CLL) to 0 (atypical for CLL). Application of the scoring system to all the cases showed that 87% of CLL scored 5 and 4 and only 0.4% scored 0 or 1, whereas 89% of other B-cell leukemias and 72% of lymphomas scored 0 or 1; only one case (0.3%) scored 4 and none scored 5 (p < 0.0001). There were no differences between CLL with high and low scores but higher scores were found in cases with more typical morphology (p < 0.0015). Considering each individual marker, there was no single one that distinguished CLL from other diseases, although the most reliable were SmIg intensity and FMC7. The proposed score will facilitate the diagnosis of B-lymphoproliferative disorders and improve their classification.
Asunto(s)
Linfocitos B/patología , Moléculas de Adhesión Celular , Lectinas , Leucemia Linfocítica Crónica de Células B/diagnóstico , Antígenos CD/análisis , Antígenos de Diferenciación de Linfocitos B/análisis , Linfocitos B/inmunología , Antígenos CD5 , Distribución de Chi-Cuadrado , Diagnóstico Diferencial , Humanos , Inmunofenotipificación , Leucemia de Células Pilosas/diagnóstico , Leucemia de Células Pilosas/inmunología , Leucemia Linfocítica Crónica de Células B/inmunología , Leucemia Prolinfocítica/diagnóstico , Leucemia Prolinfocítica/inmunología , Linfoma de Células B/diagnóstico , Linfoma de Células B/inmunología , Trastornos Linfoproliferativos/diagnóstico , Trastornos Linfoproliferativos/inmunología , Receptores de Antígenos de Linfocitos B/análisis , Receptores de IgE/análisis , Lectina 2 Similar a Ig de Unión al Ácido SiálicoRESUMEN
We have investigated the diagnostic value of fluorescence in situ hybridisation (FISH) to detect t(11;14) and trisomy 12 in 53 cases with a B cell leukaemia difficult to classify on clinical and laboratory grounds. These cases were initially diagnosed by morphology and immunophenotype and in 33 of them, on tissue histology, as follows: chronic lymphocytic leukaemia (CLL), 20, 18 of them with atypical features; B cell prolymphocytic leukaemia (B-PLL), two; mantle-cell lymphoma (MCL), 15; splenic lymphoma with villous lymphocytes (SLVL), five; lymphoplasmacytic lymphoma, six; follicular lymphoma, one and, four cases remained unclassifiable. FISH demonstrated BCL-1 rearrangement in the circulating cells from 15 cases classified as: MCL (10), atypical CLL (three) and B-PLL (two). A definitive diagnosis of MCL was made on review of the spleen histology in one out of the three atypical CLL with BCL-1 rearrangement. Trisomy 12 was detected in eight cases which included four atypical CLL, one typical CLL, two MCL and one unspecified B cell lymphoma by histology and morphology. One of the MCL had both trisomy 12 and BCL-1 rearrangement and the other was CD5+, CD23+ and had a CLL score of 3, suggesting the latter diagnosis. Our findings demonstrate that FISH analysis is useful to clarify the nature of the disease in patients presenting with a B cell leukaemia in which the diagnosis is difficult by conventional methods. FISH established with certainty the diagnosis of MCL by showing BCL-1 rearrangement in over two-thirds of cases in which this was suspected, including blastoid forms, and confirmed the diagnosis of most cases of atypical CLL.
Asunto(s)
Cromosomas Humanos Par 12/genética , Genes bcl-1/genética , Hibridación Fluorescente in Situ , Leucemia de Células B/diagnóstico , Translocación Genética/genética , Trisomía/genética , Humanos , Inmunofenotipificación , Leucemia de Células B/genética , Leucemia de Células B/patología , Leucemia Linfocítica Crónica de Células B/diagnóstico , Leucemia Linfocítica Crónica de Células B/genética , Leucemia Linfocítica Crónica de Células B/patología , Leucemia Prolinfocítica/diagnóstico , Leucemia Prolinfocítica/genética , Leucemia Prolinfocítica/patología , Linfoma de Células del Manto/diagnóstico , Linfoma de Células del Manto/genética , Linfoma de Células del Manto/patología , Linfoma no Hodgkin/diagnóstico , Linfoma no Hodgkin/genética , Linfoma no Hodgkin/patología , Masculino , Persona de Mediana EdadRESUMEN
T- cell Prolymhocytic leukemia (T-PLL) is a rare mature post-thymic T-cell malignancy that is usually reported in the elderly and follows an aggressive course. A 68 year old male presented with a history of weakness and weight loss of two months duration. Clinical examination revealed pallor, enlarged cervical and axillary lymph nodes and splenomegaly. He also had a maculo- papular skin rash. There was marked leucocytosis, anemia and thrombocytopenia (WBC 445 x 103 sub/ml, Hb 8.5 gm/dl, Platelet 25 x 103 sub/microl) with 60% prolymphocytes in the peripheral blood. Bone marrow was hypercellular with an excess of prolymphocytes. Flow cytometric analysis of the bone marrow showed positivity for CD2, CD3, CD4, CD5 and CD 7. T- PLL is a rare T cell disorder with characteristic clinical and laboratory features. Currently, no optimal treatment exists although there has been some success with 2'- deoxycoformycin or Campath-1H.
Asunto(s)
Leucemia Prolinfocítica/diagnóstico , Anciano , Células de la Médula Ósea/patología , Diagnóstico Diferencial , Humanos , Leucemia Prolinfocítica/sangre , Leucemia Prolinfocítica/patología , Masculino , Pérdida de PesoRESUMEN
In a series of 139 spleens involved by non-Hodgkin's lymphoma, we found that each type of lymphoma (as classified according to the Kiel classification) has a specific pattern of infiltration in the red and white pulp. Tumor infiltration in preexistent follicles was not a feature of B-cell lymphomas, but tumor nodules were found in the red pulp nonfiltering areas in cases of immunocytoma (small lymphocytic plasmacytoid) and centroblastic-centrocytic lymphoma (follicle center-cell lymphoma). B-chronic lymphocytic leukemia and centrocytic-centroblastic lymphoma were located along central arteries of T-cell areas. T-cell areas were infiltrated by B-prolymphocytic leukemia, immunocytoma, centrocytic lymphoma (lymphocytic lymphoma of intermediate differentiation), and T-cell lymphoma/leukemia. The red pulp showed diffuse involvement in leukemic cases. Additionally, there was pericapillary growth in all cases of low-grade B-cell lymphoma. The findings, which are related to the physiological counterparts of the lymphoma cells, contribute to our knowledge of the routes of circulation as well as the homing areas of lymphocytes in the human spleen.
Asunto(s)
Linfoma no Hodgkin/patología , Bazo/patología , Humanos , Inmunoglobulina A/metabolismo , Inmunoglobulina D/metabolismo , Inmunoglobulina G/metabolismo , Inmunoglobulina M/metabolismo , Cadenas kappa de Inmunoglobulina/metabolismo , Cadenas lambda de Inmunoglobulina/metabolismo , Inmunohistoquímica , Leucemia de Células Pilosas/diagnóstico , Leucemia de Células Pilosas/metabolismo , Leucemia de Células Pilosas/patología , Leucemia Linfocítica Crónica de Células B/diagnóstico , Leucemia Linfocítica Crónica de Células B/metabolismo , Leucemia Linfocítica Crónica de Células B/patología , Leucemia Prolinfocítica/diagnóstico , Leucemia Prolinfocítica/metabolismo , Leucemia Prolinfocítica/patología , Leucemia Prolinfocítica de Células T/diagnóstico , Leucemia Prolinfocítica de Células T/metabolismo , Leucemia Prolinfocítica de Células T/patología , Linfoma/diagnóstico , Linfoma/metabolismo , Linfoma/patología , Linfoma Folicular/diagnóstico , Linfoma Folicular/metabolismo , Linfoma Folicular/patología , Linfoma no Hodgkin/clasificación , Linfoma no Hodgkin/metabolismo , Plasmacitoma/diagnóstico , Plasmacitoma/metabolismo , Plasmacitoma/patología , Bazo/metabolismoRESUMEN
The introduction of monoclonal antibodies (mAbs) for cell immunophenotyping and use of flow cytometry with the progressively improving software for multivariate analyses have revolutionized the diagnosis and influenced the classification of hematologic neoplasms. In this review we focus on the practical application of flow cytometry in the diagnosis and classification of malignant lymphomas and related lymphoproliferative disorders with special emphasis on differential diagnosis. A general approach to the utilization of flow cytometry (FC) in hematopathology with an algorithm to diagnose the most common neoplasms is presented. We discuss precursor B-cell neoplasms, mature B-cell neoplasms (SLL/CLL, mantle cell lymphoma, marginal zone lymphoma, hairy cell leukemia, diffuse large B-cell lymphoma, plasma cell dyscrasias and lymphomas with plasmacytic differentiation), precursor T-lymphoblastic leukemia and mature (peripheral) T-cell neoplasms, including T-SLL/PLL, anaplastic cell lymphomas and large granular cell leukemia/lymphoma. The text is accompanied by characteristic FC scatterplots of the discussed entities.
Asunto(s)
Antígenos de Diferenciación/análisis , Citometría de Flujo/métodos , Perfilación de la Expresión Génica , Inmunofenotipificación/métodos , Linfoma/diagnóstico , Anticuerpos Monoclonales/inmunología , Antígenos de Diferenciación/biosíntesis , Antígenos de Diferenciación/genética , Subgrupos de Linfocitos B/química , Subgrupos de Linfocitos B/patología , Biomarcadores , Diferenciación Celular , Linaje de la Célula , Diagnóstico Diferencial , Regulación Neoplásica de la Expresión Génica , Enfermedad de Hodgkin/diagnóstico , Enfermedad de Hodgkin/patología , Humanos , Leucemia de Células Pilosas/diagnóstico , Leucemia de Células Pilosas/metabolismo , Leucemia de Células Pilosas/patología , Leucemia Prolinfocítica/diagnóstico , Leucemia Prolinfocítica/metabolismo , Leucemia Prolinfocítica/patología , Linfoma/química , Linfoma/clasificación , Linfoma/patología , Células Madre Neoplásicas/química , Células Madre Neoplásicas/patología , Plasmacitoma/diagnóstico , Plasmacitoma/metabolismo , Plasmacitoma/patología , Leucemia-Linfoma Linfoblástico de Células Precursoras B/diagnóstico , Leucemia-Linfoma Linfoblástico de Células Precursoras B/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras B/patología , Subgrupos de Linfocitos T/química , Subgrupos de Linfocitos T/patologíaRESUMEN
Chronic lymphoproliferative disorders sometimes can be difficult to classify. We report 4 cases characterized by large cells with distinct central nucleoli, reminiscent of prolymphocytic leukemia, but shown on further workup to represent mantle cell lymphoma. At initial examination, the patients had generalized lymphadenopathy, splenomegaly, and a leukemic blood picture. The peripheral blood showed many large cells with round to slightly irregular nuclei, single central nucleoli, and a fair amount of pale cytoplasm. The picture was not typical of prolymphocytic leukemia because of the presence of generalized lymphadenopathy and the large size of the circulating abnormal cells. Immunophenotypic study showed that the large lymphoid cells were CD5+ CD23- mature B cells with overexpression of cyclin D1, and cytogenetic study demonstrated the translocation t(11;14)(q13;q32) in 3 patients. Lymph node biopsy confirmed a diagnosis of mantle cell lymphoma, pleomorphic variant, in all 4 patients. This study documents the existence of an unusual leukemic form of mantle cell lymphoma with prominent nucleoli; the clinicopathologic features that distinguish it from other chronic lymphoproliferative disorders are discussed.
Asunto(s)
Nucléolo Celular/patología , Leucemia Prolinfocítica/diagnóstico , Linfoma de Células del Manto/clasificación , Linfoma de Células del Manto/diagnóstico , Anciano , Médula Ósea , Antígenos CD5/biosíntesis , Ciclina D1/biosíntesis , Diagnóstico Diferencial , Resultado Fatal , Femenino , Humanos , Inmunohistoquímica , Inmunofenotipificación , Leucemia de Células Pilosas/diagnóstico , Ganglios Linfáticos/patología , Enfermedades Linfáticas/etiología , Enfermedades Linfáticas/patología , Linfoma de Células del Manto/metabolismo , Masculino , Esplenomegalia/etiología , Translocación GenéticaRESUMEN
T-cell prolymphocytic leukemia is a rare and highly aggressive hematological neoplasm. A patient with T-cell prolymphocytic leukemia presented with bilateral perilimbal conjunctival infiltrates. Conjunctival biopsy showed aggregates of large atypical lymphocytes in the substantia propria with a concentration of atypical cells in the perivascular areas. Immunophenotyping of the malignant cells identified an abnormal clonal T-cell population consistent with T-cell prolymphocytic leukemia. A literature review of all reports of conjunctival involvement with leukemia was performed. The three cases of ocular prolymphocytic leukemia, including the one case of ocular T-cell prolymphocytic leukemia, are discussed in detail as well as 14 reported clinical cases of biopsy-proven conjunctival leukemia. The majority of cases occurred in the setting of acute leukemia, and conjunctival involvement was frequently a presenting sign of the disease or signified disease relapse. Conjunctival involvement with leukemia was consistent with good visual acuity; however, it portended a poor prognosis.
Asunto(s)
Conjuntiva/patología , Leucemia Prolinfocítica/diagnóstico , Leucemia de Células T/diagnóstico , Alemtuzumab , Antibióticos Antineoplásicos/uso terapéutico , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados , Anticuerpos Antineoplásicos/uso terapéutico , Antígenos CD/metabolismo , Antineoplásicos/uso terapéutico , Biopsia , Resultado Fatal , Humanos , Leucemia Prolinfocítica/tratamiento farmacológico , Leucemia Prolinfocítica/metabolismo , Leucemia Prolinfocítica/patología , Leucemia de Células T/tratamiento farmacológico , Leucemia de Células T/metabolismo , Leucemia de Células T/patología , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Recurrencia Local de Neoplasia , Pentostatina/uso terapéutico , RetratamientoRESUMEN
B-cell chronic lymphocytic leukemia (B-CLL) follows a heterogeneous clinical course, and several biological parameters have been investigated to try to predict its clinical outcome. New staging systems including cytogenetics and CD38 expression as predictive values have been developed. Deletions of 11q22.3 approximately q23.1 detected at diagnosis in cases of CLL patients have been associated with a relatively aggressive disease. This region, which contains the ataxia telangiectasia mutated (ATM) locus, may be implicated in the pathogenesis of lymphoid malignancies. We developed a set of dual-color specific probes to evaluate the ATM deletion by means of fluorescence in situ hybridization (FISH). We also used flow cytometry to investigate CD38 expression. Forty-one patients with CLL or low-grade B-cell lymphomas were studied at diagnosis or before treatment. FISH showed that only three CLL patients had deletions in the 11q23 locus; all three had progressive disease and were resistant to treatment. These data show that our FISH set of probes efficiently detects ATM deletions in CLL. No correlation was found between ATM deletions and CD38 expression level. These results confirm the prognostic significance of ATM deletions in CLL.
Asunto(s)
Deleción Cromosómica , Cromosomas Humanos Par 11/genética , Leucemia Linfocítica Crónica de Células B/genética , Leucemia Prolinfocítica/genética , Linfoma/genética , Proteínas Serina-Treonina Quinasas/genética , ADP-Ribosil Ciclasa/metabolismo , ADP-Ribosil Ciclasa 1 , Adulto , Anciano , Antígenos CD/metabolismo , Ataxia Telangiectasia/genética , Proteínas de la Ataxia Telangiectasia Mutada , Proteínas de Ciclo Celular , Proteínas de Unión al ADN , Progresión de la Enfermedad , Femenino , Citometría de Flujo , Estudios de Seguimiento , Humanos , Hibridación Fluorescente in Situ , Interfase , Cariotipificación , Leucemia Linfocítica Crónica de Células B/diagnóstico , Leucemia Linfocítica Crónica de Células B/terapia , Leucemia Prolinfocítica/diagnóstico , Leucemia Prolinfocítica/terapia , Linfoma/diagnóstico , Linfoma/terapia , Masculino , Glicoproteínas de Membrana , Persona de Mediana Edad , Estadificación de Neoplasias , Pronóstico , Proteínas Supresoras de TumorRESUMEN
Leukemic manifestations of mantle cell lymphoma are seen in a minority of cases, usually associated with extensive tumor. Usually the neoplastic cells in the peripheral blood resemble mantle cells with a mature chromatin pattern and irregular nuclear contours, or less frequently with a more "blastic" chromatin pattern. A prolymphocytic leukemia with t(11;14)(q13;q32) has previously been reported; however, a complete flow cytometric immunophenotypic profile was lacking. Mantle cell leukemia, prolymphocytoid type with complete flow cytometric data has not previously been described and is the purpose of this report. We report such a case in a 90 year-old female who presented with an elevated white blood cell count. The diagnosis was based on flow cytometric immunophenotyping and the cytomorphology of the peripheral blood combined with cyclin D1 immunohistochemical staining of the bone marrow. We describe our findings and her clinical course in order to heighten awareness of this previously rarely described entity.
Asunto(s)
Leucemia Prolinfocítica/patología , Linfoma de Células del Manto/patología , Anciano , Anciano de 80 o más Años , Médula Ósea/química , Cromosomas Humanos Par 11 , Cromosomas Humanos Par 14 , Ciclina D1/metabolismo , Femenino , Citometría de Flujo , Humanos , Inmunohistoquímica , Inmunofenotipificación , Leucemia Prolinfocítica/diagnóstico , Linfoma de Células del Manto/diagnóstico , Translocación Genética/genéticaRESUMEN
B-prolymphocytic leukemia (B-PLL) is an infrequent disease with a poor prognosis. We present the clinical and biological features of 41 patients. Median age was 67 years [42-89] and male-female sex ratio was 2.4. The immunophenotyping revealed B-cell phenotype, with a high level expression of surface IgM and/or IgD in all cases, FMC7+ in 76 % of cases and CD5+ in 67%. Marked spontaneous in-vitro apoptosis was observed in most cases tested (n = 12). The median overall survival time was 5 years and the event-free survival time was 37 months. As detected by univariate and multivariate analysis, the only variables associated with a poor prognosis were advanced age and anemia. No significant difference was observed between de novo PLL (n = 27) and prolymphocytoid transformation of chronic lymphocytic leukemia (n = 14). Two groups of patients were individualized according to their clinical course: patients who died within one year of diagnosis (n = 14) and patients who had a prolonged survival (n = 23) without any treatment in some cases. The comparison between the 2 groups showed that they differed in age (p = 0.01) and anemia (p = 0.02). We also observed that the patients with p53 mutations had a worse clinical outcome. Taken together these data confirm that B-PLL should be regarded as a distinct form of chronic lymphoproliferative disorder and suggest the existence of two patterns of clinical evolution.